Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Dow
Medtronic
Express Scripts
Accenture
Cantor Fitzgerald
Deloitte
Julphar
Fish and Richardson

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,829,017

« Back to Dashboard

Which drugs does patent 8,829,017 protect, and when does it expire?

Patent 8,829,017 protects XIFAXAN and is included in one NDA.

This patent has thirty-two patent family members in eleven countries.
Summary for Patent: 8,829,017
Title:Methods of treating traveler's diarrhea and hepatic encephalopathy
Abstract: Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.
Inventor(s): Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC)
Assignee: Salix Pharmaceuticals, Ltd. (Raleigh, NC)
Application Number:13/076,967
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,829,017

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,829,017

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,946,252 Methods of treating traveler's diarrhea and hepatic encephalopathy ➤ Sign Up
9,855,254 Methods of treating hepatic encephalopathy ➤ Sign Up
7,928,115 Methods of treating travelers diarrhea and hepatic encephalopathy ➤ Sign Up
9,629,828 Methods of treating traveler's diarrhea and hepatic encephalopathy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,829,017

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2571268 ➤ Sign Up
Russian Federation 2012101310 ➤ Sign Up
Russian Federation 2540513 ➤ Sign Up
Russian Federation 2011154138 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
US Army
Healthtrust
Citi
Federal Trade Commission
Colorcon
Medtronic
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.